目的 比较氨磺必利与氯氮平治疗阴性症状为主的精神分裂症的疗效及安全性。方法 以2013年5与—2016年5月河北省第六人民医院收治的阴性症状为主的精神分裂症患者166例为研究对象，根据入组顺序随机分为观察组和对照组，每组83例，对照组采用氯氮平治疗，观察组采用氨磺必利治疗，两组均连续治疗12周。比较两组在治疗2、4、8、12周时的临床疗效、阴性症状评定量表（SANS）评分和心电图异常发生率。结果 治疗4、8、12周时，观察组的治疗总有效率（37.35%、60.24%、63.86%）与对照组（39.76%、49.40%、66.27%）比较，差异均无统计学意义；治疗4、8、12周时，两组的SANS量表中的5项指标评分均较治疗前显著降低（P＜0.05），且随着治疗时间的延长，评分均呈下降趋势；治疗第4、8、12周时，观察组的情感平淡或迟钝和注意障碍评分均显著低于对照组（P＜0.05），但两组间思维贫乏、意志缺乏和兴趣/社交缺乏评分比较，差异均无统计学意义。治疗12周时，观察组的心电图异常率显著低于对照组（P＜0.05）。结论 与氯氮平相比，氨磺必利治疗以阴性症状为主的精神分裂症的临床疗效相当，但改善情感平淡或迟钝和注意障碍效果更显著，且心电图异常发生率低。

Objective To investigate the efficacy and safety of amisulpride and clozapine in schizophrenia patients with predominantly negative symptoms. Methods Totally 166 cases of schizophrenia patients with predominantly negative symptoms from May 2013 to May 2016 in The Sixth People's Hospital of Hebei were divided into observation group and control group, 83 cases in each group. Patients in the observation group were treated with amisulpride, and control group were treated with clozapine. The clinical effect, SANS scores, and occurring rate of abnormal electrocardiogram were compared. Results The clinical effect, emotional insipid (blunting), and attention dysfunction scores from SANS of observation group were significantly better than those of control group on week 4, 8, and 12, respectively (P< 0.05); The occurring rate of abnormal electrocardiogram in observation group was significantly lower than that of control group on week 12 (P< 0.05). Conclusion Compared with clozapine, amisulprid has better efficacy and safety in schizophrenia patients with predominantly negative symptoms, and can effectively improve of symptom of insipid (blunting) and attention dysfunction.